Drug Trial Radar · NCT04858334
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
152
Planned (sponsor's estimate)
Start
Jun 22, 2021
Primary completion
Oct 31, 2027
Study completion Oct 31, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Apr 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Conditions
- Pancreatic Acinar Cell Carcinoma
- Pancreatic Adenosquamous Carcinoma
- Pancreatic Squamous Cell Carcinoma
- Resectable Pancreatic Acinar Cell Carcinoma
- Resectable Pancreatic Adenocarcinoma
- Resectable Pancreatic Adenosquamous Carcinoma
- Resectable Pancreatic Carcinoma
Interventions
Biospecimen CollectionProcedure
Undergo collection of blood
Computed TomographyProcedure
Undergo CT or CT/MRI
Magnetic Resonance ImagingProcedure
Undergo CT/MRI
OlaparibDrug
Given PO
Placebo AdministrationDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement in relapse-free survival (RFS)Time frame: From randomization to first documentation of disease recurrence (primary tumor relapse) or death, assessed from 22 months to 44 months
Locations
457 sites in 3 countries. Site status is shown where the registry gives one.
Anchorage Associates in Radiation Medicine
Anchorage, Alaska · Suspended
Anchorage Radiation Therapy Center
Anchorage, Alaska · Suspended
Alaska Breast Care and Surgery LLC
Anchorage, Alaska · Suspended
Alaska Oncology and Hematology LLC
Anchorage, Alaska · Suspended
Alaska Women's Cancer Care
Anchorage, Alaska · Suspended
Anchorage Oncology Centre
Anchorage, Alaska · Suspended
Katmai Oncology Group
Anchorage, Alaska · Suspended
Providence Alaska Medical Center
Anchorage, Alaska · Suspended
Fairbanks Memorial Hospital
Fairbanks, Alaska · Suspended
Kingman Regional Medical Center
Kingman, Arizona · Recruiting
Cancer Center at Saint Joseph's
Phoenix, Arizona · Active not recruiting
Mercy Hospital Fort Smith
Fort Smith, Arkansas · Suspended
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas · Suspended
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas · Suspended
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California · Active not recruiting
PCR Oncology
Arroyo Grande, California · Suspended
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California · Recruiting
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California · Suspended
Palo Alto Medical Foundation-Fremont
Fremont, California · Recruiting
Memorial Medical Center
Modesto, California · Recruiting
Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California · Suspended
Saint Joseph Hospital - Orange
Orange, California · Recruiting
Sutter Roseville Medical Center
Roseville, California · Recruiting
Sutter Medical Center Sacramento
Sacramento, California · Recruiting
California Pacific Medical Center-Pacific Campus
San Francisco, California · Recruiting
Pacific Central Coast Health Center-San Luis Obispo
San Luis Obispo, California · Active not recruiting
Mills Health Center
San Mateo, California · Recruiting
Palo Alto Medical Foundation-Santa Cruz
Santa Cruz, California · Recruiting
Mission Hope Medical Oncology - Santa Maria
Santa Maria, California · Active not recruiting
Providence Medical Foundation - Santa Rosa
Santa Rosa, California · Recruiting
Sutter Pacific Medical Foundation
Santa Rosa, California · Recruiting
Providence Santa Rosa Memorial Hospital
Santa Rosa, California · Suspended
Palo Alto Medical Foundation-Sunnyvale
Sunnyvale, California · Recruiting
Northbay Cancer Center
Vacaville, California · Recruiting
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado · Active not recruiting
Rocky Mountain Cancer Centers-Penrose
Colorado Springs, Colorado · Active not recruiting
AdventHealth Porter
Denver, Colorado · Suspended
CommonSpirit Cancer Center Mercy
Durango, Colorado · Active not recruiting
Mercy Medical Center
Durango, Colorado · Active not recruiting
CommonSpirit Saint Anthony Hospital Cancer Center
Lakewood, Colorado · Active not recruiting
Showing 40 of 457 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.